FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118202335> ?p ?o ?g. }

• W3118202335 abstract "Introduction. Neovascular glaucoma (NVG) is one of the most prognostically unfavorable forms of the glaucomatous process. The leading pathogenetic mechanism for the development of NVH is hypoxia of the inner layers of the retina, leading to the development of endothelial vascular growth factors (VEGF), which induce neovascular proliferation. In the presence of newly formed vessels in the corner of the anterior chamber, the use of traditional surgical methods for treating glaucoma is limited. That is why the search for a new pathogenetically oriented methods for the treatment of NVH is still acute issue in ophthalmology. Purpose. To evaluate the preliminary results of combined treatment, including intraocular introduction of anti-VEGF therapies (ranibizumab) and micropulse cyclophotocoagulation, in patients with secondary neovascular glaucoma. Materials and methods. The study included 15 patients (15 eyes) with secondary neovascular glaucoma. The value of intraocular pressure (IOP) before surgery ranged from 28 to 44 mm Hg. (average 36.3 ± 4.4 mm Hg), the number of hypotensive drops was 3.5 ± 0.5. The combine treat of patients including the intraocular administration of a VEGF inhibitor (ranibizumab) and through 7-14 days transscleral diode-laser cyclophotocoagulation in micropulse mode on the device «Cyclo G6 Glaucoma Laser System» (IRIDEX, USA) with a laser power of 2000 mW, an exposition of 160 s (80 s in each hemisphere) and a duty cycle of 31.3%. Results. All treatment procedures were performed without complications. By 6 months of follow-up, the average IOP level was 26.9 ± 3.3 mm Hg, the number of hypotensive drops was reduced to 2.7 ± 0.7 drugs. By 1 month of observation, a decrease in the number of newly formed vessels of the iris was achived in all patients. According to ultrasound biomicroscopy, the thickness of the ciliary body (CT) before treatment was on average 0.58 ± 0.14 mm. By 6 months of follow-up, no cases of postoperative atrophy of CT was diagnosed, the thickness of the CT was on average 0.53 ± 0.11 mm. According to the data of optical coherence tomography in the angiography mode, in all cases there was a positive dynamic in 1 month after combined treatment - a significant decrease in macular edema, the area of the retinal nonperfusion zone and the number of newly formed vessels. Conclusion. Combined treatment of patients with secondary neovascular glaucoma, including intraocular introduction of anti-VEGF therapies and micropulse cyclophotocoagulation, is an effective and safe method for reducing IOP." @default.
• W3118202335 created "2021-01-05" @default.
• W3118202335 creator A5001436632 @default.
• W3118202335 creator A5051619332 @default.
• W3118202335 creator A5081985240 @default.
• W3118202335 date "2020-01-20" @default.
• W3118202335 modified "2023-10-14" @default.
• W3118202335 title "Micropulse Transscleral Cyclophotocoagulation in the Combine Treatment of Neovascular Glaucoma" @default.
• W3118202335 doi "https://doi.org/10.25276/2227-8281-1-71-75" @default.
• W3118202335 hasPublicationYear "2020" @default.
• W3118202335 type Work @default.
• W3118202335 sameAs 3118202335 @default.
• W3118202335 citedByCount "3" @default.
• W3118202335 countsByYear W31182023352020 @default.
• W3118202335 countsByYear W31182023352021 @default.
• W3118202335 crossrefType "journal-article" @default.
• W3118202335 hasAuthorship W3118202335A5001436632 @default.
• W3118202335 hasAuthorship W3118202335A5051619332 @default.
• W3118202335 hasAuthorship W3118202335A5081985240 @default.
• W3118202335 hasConcept C118487528 @default.
• W3118202335 hasConcept C134018914 @default.
• W3118202335 hasConcept C141071460 @default.
• W3118202335 hasConcept C2776694085 @default.
• W3118202335 hasConcept C2776766258 @default.
• W3118202335 hasConcept C2777802072 @default.
• W3118202335 hasConcept C2778527774 @default.
• W3118202335 hasConcept C2779829184 @default.
• W3118202335 hasConcept C2781092963 @default.
• W3118202335 hasConcept C2781100027 @default.
• W3118202335 hasConcept C3020578304 @default.
• W3118202335 hasConcept C555293320 @default.
• W3118202335 hasConcept C71924100 @default.
• W3118202335 hasConceptScore W3118202335C118487528 @default.
• W3118202335 hasConceptScore W3118202335C134018914 @default.
• W3118202335 hasConceptScore W3118202335C141071460 @default.
• W3118202335 hasConceptScore W3118202335C2776694085 @default.
• W3118202335 hasConceptScore W3118202335C2776766258 @default.
• W3118202335 hasConceptScore W3118202335C2777802072 @default.
• W3118202335 hasConceptScore W3118202335C2778527774 @default.
• W3118202335 hasConceptScore W3118202335C2779829184 @default.
• W3118202335 hasConceptScore W3118202335C2781092963 @default.
• W3118202335 hasConceptScore W3118202335C2781100027 @default.
• W3118202335 hasConceptScore W3118202335C3020578304 @default.
• W3118202335 hasConceptScore W3118202335C555293320 @default.
• W3118202335 hasConceptScore W3118202335C71924100 @default.
• W3118202335 hasLocation W31182023351 @default.
• W3118202335 hasOpenAccess W3118202335 @default.
• W3118202335 hasPrimaryLocation W31182023351 @default.
• W3118202335 hasRelatedWork W12030477 @default.
• W3118202335 hasRelatedWork W12704620 @default.
• W3118202335 hasRelatedWork W14047651 @default.
• W3118202335 hasRelatedWork W1533687 @default.
• W3118202335 hasRelatedWork W16603326 @default.
• W3118202335 hasRelatedWork W21704865 @default.
• W3118202335 hasRelatedWork W6803863 @default.
• W3118202335 hasRelatedWork W7105194 @default.
• W3118202335 hasRelatedWork W19675674 @default.
• W3118202335 hasRelatedWork W8106635 @default.
• W3118202335 isParatext "false" @default.
• W3118202335 isRetracted "false" @default.
• W3118202335 magId "3118202335" @default.
• W3118202335 workType "article" @default.